comprehensive -WSS

comprehensive

author：explore 2025-08-26 23:47:24 - browse：47

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： A new ‘biological computer' targets cancer while sparing healthy cells

WSS

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

How a Boston hospital is priming medical residents to use GPT

‘The Bear’ and hospitality in hospitals

Caribou posts encouraging results on off

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Discs beat pads, tampons for heavy menstrual flow, new study shows

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Medical records are filled with copy

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Walensky prepares to leave CDC — and Congress — behind

CDC launches VaccineFinder tool to locate Covid

Bright Health sells Medicare Advantage business to Molina

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dementia risk linked to living in disadvantaged areas: Study

Medical leaders decry Supreme Court decision on affirmative action

In rare move, senator releases unverified FBI source report alleging Biden bribe

entertainment

'CMA Fest' 2023: How to watch, who is performing and more

FTX founder Sam Bankman

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

A new ‘biological computer' targets cancer while sparing healthy cells

leisure time

leisure time

hotspot

Wikipedia